The global vas occlusive crisis associated with sickle cell disease drug market is expected to grow at a CAGR of 5.5% during the forecast period, from 2021 to 2030. The market is driven by factors such as increasing prevalence of sickle cell disease and rising awareness about the condition. The high cost of treatment for vas occlusive crisis associated with sickle cell disease is also driving the growth of this market. The global vas occlusive crisis associated with sickle cell disease drug market has been segmented on the basis of type, application, and region. On the basis of type, it has been segmented into SG2083, Crizanlizumab, P04447943 and NV508. On the basis of application it has been segmented into clinic and hospital. On the basis of region it has been segmented into North America (NA), Latin America (LA), Europe (EU), Asia Pacific (APAC) and Middle East & Africa (MEA).
Some Of The Growth Factors Of This Market:
- Vaso-occlusive crises are caused by blood cells blocking small blood vessels in various organs such as kidneys or lungs due to abnormal shape and size of red blood cells (sickle cells) that cause them not being able to flow through small vessels easily; this leads them into clumping together and forming blockages which can lead into organ failure if not treated on time; these crises can be prevented by taking medication before they happen or when they start happening; this will help prevent organ damage or even death if left untreated.
- The most common treatment for vaso-occlusive crises associated with sickle cell disease includes oxygen therapy, pain relief medications such as morphine or hydromorphone, fluids given intravenously (IV), transfusions of red blood cells.
Industry Growth Insights published a new data on “Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market”. The research report is titled “Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market research by Types (SGD-2083, Crizanlizumab, PF-04447943, NVX-508, Others), By Applications (Clinic, Hospital, Others), By Players/Companies AstraZeneca Plc, Bristol-Myers Squibb Company, Gilead Sciences Inc, Modus Therapeutics Holding AB, Novartis AG, NuvOx Pharma LLC, Pfizer Inc, Seattle Genetics Inc”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Research Report
By Type
SGD-2083, Crizanlizumab, PF-04447943, NVX-508, Others
By Application
Clinic, Hospital, Others
By Companies
AstraZeneca Plc, Bristol-Myers Squibb Company, Gilead Sciences Inc, Modus Therapeutics Holding AB, Novartis AG, NuvOx Pharma LLC, Pfizer Inc, Seattle Genetics Inc
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
245
Number of Tables & Figures
172
Customization Available
Yes, the report can be customized as per your need.
Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Report Segments:
The global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug market is segmented on the basis of:
Types
SGD-2083, Crizanlizumab, PF-04447943, NVX-508, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Clinic, Hospital, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- AstraZeneca Plc
- Bristol-Myers Squibb Company
- Gilead Sciences Inc
- Modus Therapeutics Holding AB
- Novartis AG
- NuvOx Pharma LLC
- Pfizer Inc
- Seattle Genetics Inc
Highlights of The Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- SGD-2083
- Crizanlizumab
- PF-04447943
- NVX-508
- Others
- By Application:
- Clinic
- Hospital
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
A vaso-occlusive crisis is a life-threatening complication of sickle cell disease (SCD) that can occur when the body's blood vessels become blocked by sickle cells. Vaso-occlusive crises can cause shortness of breath, chest pain, and even death. Treatment for vaso-occlusive crises includes emergency room visits and sometimes surgery.
Some of the major companies in the vaso-occlusive crisis associated with sickle cell disease drug market are AstraZeneca Plc, Bristol-Myers Squibb Company, Gilead Sciences Inc, Modus Therapeutics Holding AB, Novartis AG, NuvOx Pharma LLC, Pfizer Inc, Seattle Genetics Inc.
The vaso-occlusive crisis associated with sickle cell disease drug market is expected to register a CAGR of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market - Supply Chain
4.5. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Forecast
4.5.1. Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size (000 Units) and Y-o-Y Growth
4.5.3. Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Absolute $ Opportunity
5. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size and Volume Forecast by Type
5.3.1. SGD-2083
5.3.2. Crizanlizumab
5.3.3. PF-04447943
5.3.4. NVX-508
5.3.5. Others
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size and Volume Forecast by Application
6.3.1. Clinic
6.3.2. Hospital
6.3.3. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Demand Share Forecast, 2019-2026
9. North America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size and Volume Forecast by Application
9.4.1. Clinic
9.4.2. Hospital
9.4.3. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size and Volume Forecast by Type
9.7.1. SGD-2083
9.7.2. Crizanlizumab
9.7.3. PF-04447943
9.7.4. NVX-508
9.7.5. Others
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Demand Share Forecast, 2019-2026
10. Latin America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size and Volume Forecast by Application
10.4.1. Clinic
10.4.2. Hospital
10.4.3. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size and Volume Forecast by Type
10.7.1. SGD-2083
10.7.2. Crizanlizumab
10.7.3. PF-04447943
10.7.4. NVX-508
10.7.5. Others
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Demand Share Forecast, 2019-2026
11. Europe Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size and Volume Forecast by Application
11.4.1. Clinic
11.4.2. Hospital
11.4.3. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size and Volume Forecast by Type
11.7.1. SGD-2083
11.7.2. Crizanlizumab
11.7.3. PF-04447943
11.7.4. NVX-508
11.7.5. Others
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Demand Share, 2019-2026
12. Asia Pacific Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size and Volume Forecast by Application
12.4.1. Clinic
12.4.2. Hospital
12.4.3. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size and Volume Forecast by Type
12.7.1. SGD-2083
12.7.2. Crizanlizumab
12.7.3. PF-04447943
12.7.4. NVX-508
12.7.5. Others
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Demand Share, 2019-2026
13. Middle East & Africa Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size and Volume Forecast by Application
13.4.1. Clinic
13.4.2. Hospital
13.4.3. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size and Volume Forecast by Type
13.7.1. SGD-2083
13.7.2. Crizanlizumab
13.7.3. PF-04447943
13.7.4. NVX-508
13.7.5. Others
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market: Market Share Analysis
14.2. Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Distributors and Customers
14.3. Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. AstraZeneca Plc
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Bristol-Myers Squibb Company
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Gilead Sciences Inc
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Modus Therapeutics Holding AB
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Novartis AG
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. NuvOx Pharma LLC
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Pfizer Inc
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Seattle Genetics Inc
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20<